Senti Biosciences Reports $12.8 Million Net Loss in Q2 2026, Announces Merger Agreement

Senti Biosciences Holdings, Inc. reported a net loss of $12.8 million for the second quarter of 2026, a decrease from a loss of $14.7 million in the same period of 2025. For the first half of 2026, the company recorded a net loss of $17.0 million, down from $28.8 million in the prior year. The reduction in losses is attributed to a significant decrease in operating expenses, which totaled $14.5 million for the quarter, compared to $16.8 million a year earlier. The company generated $17,000 in collaboration revenue from a related party during the quarter, marking its first revenue recognition.

Senti's total operating expenses for the first half of 2026 were $19.1 million, down from $33.2 million in the same period of 2025. The decrease was primarily driven by a reduction in research and development expenses, which fell to $13.0 million from $19.3 million year-over-year. This decline was largely due to lower external service costs associated with the development of its lead product candidate, SENTI-202. General and administrative expenses also decreased slightly, reflecting ongoing efforts to manage costs effectively.

The company’s financial position showed a significant decline in cash and cash equivalents, which decreased to $6.5 million as of June 30, 2026, from $16.4 million at the end of 2025. This decline is attributed to net cash used in operating activities of $21.7 million during the first half of 2026, although the company did receive $9.6 million in financing from the issuance of convertible notes. Senti's accumulated deficit increased to $375.5 million, up from $358.6 million at the end of 2025.

Strategically, Senti has undergone a holding company reorganization and entered into a merger agreement with an affiliate of its largest stockholder, Celadon Partners. This merger, expected to close pending stockholder approval, will allow Senti to retain certain intellectual property and early-stage programs while merging its existing business into a private entity. The merger agreement includes provisions for contingent value rights that could provide up to $60 million in cash payments based on the achievement of specific milestones related to SENTI-202.

Looking ahead, Senti anticipates continued operating losses and negative cash flows as it advances its clinical development programs. The company has indicated that it will require additional funding to maintain operations and support its research and development activities. Management is actively pursuing financing options, but substantial doubt exists regarding its ability to continue as a going concern without securing further capital.